comparemela.com

Latest Breaking News On - Chrs - Page 24 : comparemela.com

Sargent Investment Group LLC Sells 3,970 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Sargent Investment Group LLC trimmed its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) by 26.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,200 shares of the biotechnology company’s stock after selling 3,970 shares during the period. Sargent Investment Group LLC’s holdings in […]

Kentucky
United-states
Doug-farrar
Coherus-biosciences
Steve-glover
Dennism-lanfear
Alan-herman
Barclays
Nasdaq
Sargent-investment-group
Coherus-biosciences-inc
York-mellon-corp

Coherus BioSciences (NASDAQ:CHRS) Shares Down 3.1%

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) were down 3.1% on Tuesday . The company traded as low as $7.58 and last traded at $7.60. Approximately 218,070 shares traded hands during trading, a decline of 81% from the average daily volume of 1,132,020 shares. The stock had previously closed at $7.84. Analysts Set […]

Steve-glover
Doug-farrar
Dennism-lanfear
Alan-herman
Coherus-biosciences
Nasdaq
Alpine-global-management
Hermes-inc
Coherus-biosciences-inc
Eagle-bay-advisors
Barclays
Verition-fund-management

Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 […]

Doug-farrar
Dennism-lanfear
Steve-glover
Alan-herman
Coherus-biosciences
Hermes-inc
Coherus-biosciences-inc
Nasdaq
Eagle-bay-advisors
Barclays
Verition-fund-management
Alpine-global-management

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among […]

Wisconsin
United-states
Alan-herman
Dennism-lanfear
Doug-farrar
Steve-glover
Coherus-biosciences
Susquehanna-fundamental-investments
Barclays
Nasdaq
Mackenzie-financial-corp
Coherus-biosciences-company-profile

Coherus BioSciences (NASDAQ:CHRS) Shares Up 6.6%

Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating)’s share price traded up 6.6% during trading on Monday . The company traded as high as $7.33 and last traded at $7.29. 473,528 shares were traded during trading, a decline of 58% from the average session volume of 1,136,560 shares. The stock had previously closed at $6.84. Analysts […]

Dennism-lanfear
Alan-herman
Steve-glover
Coherus-biosciences
Doug-farrar
Alpine-global-management
Hermes-inc
Barclays
Eagle-bay-advisors
Verition-fund-management
Nasdaq
Coherus-biosciences-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.